Pharmacological profiles of latanoprost (Xalatan(TM)), a novel anti- glaucoma drug

Folia Pharmacologica Japonica

Volumn 115, Issue 5, 2000, Pages 280-286

  Nomura, Shunji ^a   Hashimoto, Munehiro ^a  

^a National Center of Neurology and Psychiatry   (Japan)

Author keywords

Glaucoma; Intraocular pressure; Latanoprost; Prostaglandin F(2 ); Uveoscleral outflow

Indexed keywords

ANTIGLAUCOMA AGENT; LATANOPROST; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN F2 ALPHA DERIVATIVE; RECEPTOR SUBTYPE; TIMOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR FLOW; BRAIN PROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GLAUCOMA; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MONKEY; NONHUMAN; PHASE 3 CLINICAL TRIAL; REVIEW; SPECIES DIFFERENCE;

EID: 0034110674     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.115.280     Document Type: Review

References (32)

1. Stjernschantz J and Bito LZ: The ocular effects of eicosanoids and other autacoids: historic background and the need for a broader perspective. In The Ocular Effects of Prostaglandins and Other Eicosanoids, Edited by Bito LZ and Stjernschantz J, pp 1-13, Alan R Liss Inc, New York (1989)
2. Bito LZ, Camras CB, Gum GG and Resul B: The ocular hypotensive effects and side effects of prostaglandins on the eyes of experimental. In The Ocular Effects of Prostaglandins and Other Eicosanoids, Edited by Bito LZ and Stjernschantz J, pp 349-368, Alan R Liss Inc, New York (1989)
3. Camras CB, Bito LZ and Eakins KE: Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest Ophthalmol Vis Sci 16, 1125-1134 (1977)
4. Camras CB and Aim A: Initial clinical studies with prostaglandins and their analogues. Surv Ophthalmol 41, S61-S68 (1997)
5. Resul B, Stjernschantz J, No K, Liljebris C, Selén G, Astin M, Karlsson M and Bito LZ: Phenylsubstituted prostaglandins: Potent and selective antiglaucoma agents. J Med Chem 36, 243-248 (1993)
6. Coleman RA, Kennedy I, Humphrey PPA, Bunce K and Lumley P: Prostanoids and their receptors. In Comprehensive Medicinal Chemistry, Edited by Hansch C, Sammes PG and Taylor JB, Vol 3, pp 643-714, Pergamon Press, Oxford New York (1989)
7. 2α analogue. Adv Leukot Res 23, 513-518 (1995)
8. Goh Y and Kishino J: Pharmacological characterization of prostaglandin-related ocular hypotensive agents. Jpn J Ophthalmol 38, 236-245 (1994)
9. Stjernschantz J and Resul B: Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs of the Future 17, 691-704 (1992)
10. Serie JB, Podos SM, Kitazawa Y and Wang R-F: A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Jpn J Ophthalmol 42, 95-100 (1998)
11. 2α effects on intraocular pressure negatively correlate with FP-receptor stimulation. Invest Ophthalmol Vis Sci 30, 1838-1842 (1989)
12. Kaufman HE: Timolol maleate. Ophthalmology 87, 164-168 (1980)
13. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 49, 389-402 (1989)
14. Bill A: Uveoscleral drainage of aqueous humor: physiology and pharmacology. In The Ocular Effects of Prostaglandins and Other Eicosanoids, Edited by Bito LZ and Stjernschantz J, pp 417-427, Alan R Liss Inc, New York (1989)
15. 2α receptor messenger RNA and protein in the cynomolgus monkey eye. Invest Ophthalmol Vis Sci 37, 716-726 (1996)
16. 2 binding sites in the human eye. Br J Ophthalmol 76, 210-213 (1992)
17. 2 receptor is the predominant prostanoid receptor in the human ciliary muscle. Br J Ophthalmol 77, 110-114 (1993)
18. 2α. Exp Eye Res 47, 761-769 (1988)
19. Lindsey JD, Kashiwagi K, Kashiwagi F and Weinreb RN: Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci 38, 2214-2223 (1997)
20. Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukahara S and Lindsey JD: Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 38, 2772-2780 (1997)
21. Ocklind A: Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 67, 179-191 (1998)
22. 2α effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci 36, 2461-2465 (1995)
23. 2 and DP receptors. Invest Ophthalmol Vis Sci 33, 3195-3201 (1992)
24. Flammer J: The vascular concept of glaucoma. Surv Ophthalmol 38, S3-S6 (1994)
25. Iadecola C: Molecular pathology of cerebral ischemia: delayed gene expression and strategies for neuroprotection. Ann N Y Acad Sci 835, 203-217 (1997)
26. Drago F, Marino A, Floriddia ML and Marino V: Latanoprost exerts neuroprotective activity in vitro and in vivo. Invest Ophthalmol Vis Sci 40, S265 (1999)
27. Stjernschantz J, Nilsson SFE and Astin M: Vasodynamic and angiogenic effects of eicosanoids in the eye. In The Ocular Effects of Prostaglandins and Other Eicosanoids, Edited by Bito LZ and Stjernschantz J, pp 155-170, Alan R Liss Inc, New York (1989)